Lr-Prp is named as an intervention in 2 current clinical trials in our Italy and Brazil registers. 1 is recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Istituto Ortopedico Rizzoli (1). The most-studied condition is Tennis Elbow.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis
NCT06040203 · ClinicalTrials.gov ↗ · Tennis Elbow
|
Not applicable | Recruiting | Istituto Ortopedico Rizzoli | Italy |
|
Effect of Nonsteroidal Anti-Inflammatory Drug Restriction on the Efficacy of Platelet-Rich Plasma in Knee Osteoarthritis
NCT07766330 · ClinicalTrials.gov ↗ · Osteoarthritis, Knee
|
Not applicable | Not yet open | Federal University of São Paulo | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Istituto Ortopedico Rizzoli | 1 |
| Federal University of São Paulo | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Italy and Brazil registers name Lr-Prp as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Istituto Ortopedico Rizzoli (1) and Federal University of São Paulo (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lr-Prp works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lr-Prp works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lr-Prp (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.